Created at 5:24 p.m. Apr, 03, 2026
Author: nataliea19
Related Note: 1506457874779 1
Rationale for change

AMBOSS is now testing Nirsevimab, not Palivizumab.

Question explanation:
Nirsevimab is a monoclonal antibody against RSV F protein, used to prevent severe disease in infants at high risk for severe RSV infection (e.g., those with a history of prematurity and/or hemodynamically significant heart disease). RSV prophylaxis provides passive immunization by neutralizing and inhibiting the fusion activity of RSV, which decreases viral replication. Nirsevimab is long acting, providing protection for 5 months, and is therefore typically administered during or just before RSV season. Palivizumab can be used as an alternative, but because it is short acting, this drug must be administered monthly during RSV season.
Source: AMBOSS - https://next.amboss.com/us/shared/questions/grvWaFgYnj/57

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Empty field
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Textbooks::#Mims_Microbiology::20_Lower_Respiratory_Tract_Infections #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Physeo::06_Micro::05_Viruses::30_Respiratory_Syncytial_Virus_(RSV)_&_Human_Metapneumovirus_(hPMV) #AK_Other::#AK_Original_Decks::Step_1::Lolnotacop::Bugs #AK_Step1_v12::#AMBOSS::Xaa9QQ #AK_Step1_v12::#FirstAid::03_Microbiology::05_Virology::15_Paramyxoviruses #AK_Step2_v12::#Bootcamp::Pediatrics::02_General_Pediatrics::01_Primary_Care::05_Vaccination #PANCE::PULM::infectious_disorders #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#SketchyMicro::03_Viruses::04_Retired_Lessons::09_Measles_virus,_mumps_virus,_respiratory_syncytial_virus,_parainfluenza_virus_(Paramyxoviridae)_[Retired_Video] #AK_Step1_v12::#B&B::20_Pulm::03_Other_Pulmonary_Topics::02_Pneumonia_II #AK_Step1_v12::#Pixorize::04_Microbiology::08_Viruses-RNA_Viruses::24_Respiratory_Syncytial_Virus_(RSV) #AK_Step1_v12::#Textbooks::#Mims_Microbiology::31_Infections_in_the_Compromised_Host #AK_Step2_v12::#Resources_by_rotation::Peds::emma #AK_Step2_v12::#AMBOSS::2DaTd5 #AK_Step1_v12::#Bootcamp::Microbiology::29_Negative-sense_RNA_Viruses::05_Respiratory_Syncytial_Virus #AK_Step1_v12::#FirstAid::02_Immunology::04_Immunosuppressants::03_Therapeutic_antibodies::*Palivizumab #AK_Step2_v12::!Shelf::Peds::no_dupes #AK_Step2_v12::Original_decks::Dorian::peds::emma #AK_Step1_v12::#FirstAid::03_Microbiology::05_Virology::09_RNA_viruses #AK_Step2_v12::#AMBOSS::gQ0Fvf #AK_Step1_v12::#SketchyMicro::03_Viruses::02_RNA_(-)_Sense::03_Respiratory_Syncytial_Virus_&_Human_Metapneumovirus_(Pneumoviridae) #PANCE::EOR::PEDS #AK_Step1_v12::#AMBOSS::FjagXk #AK_Step2_v12::#SketchyPeds::09_Infectious_Diseases::03_Ear,_Nose,_Throat,_&_Respiratory_Infections::02_Bronchiolitis #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Infectious_Disease::Pneumonia #AK_Step2_v12::#Bootcamp::Pediatrics::03_Infectious_Disease::02_Airway_and_Respiratory_Infections::01_Viral_Respiratory_Infections_in_Children #AK_Step1_v12::#UWorld::Step::1668 #AK_Step1_v12::#UWorld::COMLEX::24779